Project Grant R21CA279068
Award Date
9/8/23
Completion Date
8/31/25
Dollars Obligated
$423K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
The National Cancer Institute awarded a $644,034 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The General Hospital Corporation (Massachusetts General Hospital) to develop a nanoparticle-based drug delivery platform that uses radiation therapy to control the local and sustained release of chemotherapy payloads within irradiated tumor tissue. The goal is to expand the therapeutic window of chemoradiation by improving local disease control while mitigating systemic toxicities. The...
The National Cancer Institute (NCI) awarded a $1,003,173 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Radiopharmaceutical Imaging And Dosimetry, LLC, a for-profit limited liability company based in Baltimore, Maryland. The grant, awarded from February 1, 2025 to January 31, 2027, aims to develop a prototype web/cloud-based quantitative SPECT reconstruction software system for clinical trials and dosimetry of emerging radiopharmaceutical cancer therapies,...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), will support research on improving the safety and efficacy of chemoradiotherapy for locally advanced head and neck squamous cell carcinoma and anaplastic thyroid cancer. The key products/services to be delivered include: Evaluating how fractionated radiation affects the tumor microenvironment and impacts passive drug delivery, using in vivo imaging, microscopy, and...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), was awarded a $577,094 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research aimed at "Redirecting Viral Immunity to Eradicate Low Tumor Mutation Burden Lung Cancers." The award period runs from Aug 31, 2023 to Aug 29, 2025. As a leading academic medical center and research institution, MGH utilizes its...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $1,344,298 Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The funding will support research to optimize the image quality of mobile photon-counting CT (PCCT) scanners used in neuro intensive care units. The project aims to leverage deep...
The U.S. Department of Defense's Defense Health Agency awarded a $1,498,368 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to elucidate molecular mechanisms of tumor-immune dynamics and evolution in response to radiation in order to optimize treatment of high- and very high-risk prostate cancer. The award period runs from August 1, 2024 to July 31, 2027. As a...
The General Hospital Corporation, doing business as Massachusetts General Hospital, received a $1,255,920 Project Grant award from the Department of the Army Medical Command on February 1, 2022, with a completion date of January 31, 2026. The grant was awarded under the Military Medical Research and Development program to support innovative biomedical research that transforms military and public health care. Specifically, the funding will support research to develop synergistic prostate-specific...
This $693,781 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), aims to advance the understanding and treatment of cancers with mutations in the IDH1 gene. The key objectives are to: Further study how mutant IDH1 and the metabolite 2-hydroxyglutarate it produces enable cancer cells to evade the immune system, while IDH1 inhibitors can cause immune...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program provides $819,980.00 in funding to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on elucidating sex differences in melanoma tumorigenesis. The 3-year research project, beginning on August 15, 2024 and ending on August 14, 2027, aims to advance the understanding and treatment of this complex...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), has been awarded a $1,000,236.00 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant, effective April 1, 2024 through March 31, 2028, will fund research to "UNLOCK THE CTDNA MUTATIONAL PATTERNS FOR EARLY CANCER DETECTION AND NONINVASIVE BIOMARKERS." As a leading academic medical center and research...